Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $69
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Incyte (NASDAQ:INCY) and raises the price target from $64 to $69.
October 30, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on Incyte and increased the price target from $64 to $69, indicating a positive outlook.
The increase in price target from $64 to $69 by Morgan Stanley suggests a positive outlook for Incyte, which could lead to a short-term increase in stock price. The maintained Equal-Weight rating indicates a balanced view, but the raised target price is a positive signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100